Artivion (NYSE:AORT) Insider John Davis Sells 3,773 Shares

February 26, 2026 by InsiderTrades.com

Key Points

CEO James Mackin sold 20,962 shares on Feb. 23 at an average price of $37.59 for $787,961.58, trimming his stake by 2.62% to 780,031 shares (worth about $29.3M).
Multiple insiders conducted open‑market sales across Feb. 23–24 (the CEO sold a total of 34,898 shares, ~ $1.29M), a breadth of selling that could weigh on sentiment despite lower short interest.
Fundamentals remain positive: Artivion beat quarterly estimates with $0.17 EPS and $118.3M revenue (revenue +19.2% YoY), and analysts maintain a consensus "Moderate Buy" with a $48.97 target price.

Artivion, Inc. (NYSE:AORT - Get Free Report) insider John Davis sold 3,773 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $37.59, for a total transaction of $141,827.07. Following the completion of the sale, the insider directly owned 190,943 shares in the company, valued at approximately $7,177,547.37. This represents a 1.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Artivion Trading Up 2.7%

NYSE:AORT traded up $0.98 during mid-day trading on Thursday, hitting $36.76. 30,985 shares of the stock traded hands, compared to its average volume of 389,761. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $48.25. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of 183.81 and a beta of 1.59. The firm's 50 day moving average is $42.27 and its two-hundred day moving average is $43.08.

Artivion (NYSE:AORT - Get Free Report) last announced its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. The business's revenue for the quarter was up 19.2% compared to the same quarter last year. On average, equities research analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Artivion from a "buy" rating to a "hold" rating in a research note on Saturday, February 14th. Weiss Ratings upgraded shares of Artivion from a "sell (d)" rating to a "hold (c-)" rating in a research note on Friday, February 20th. Citizens Jmp raised their target price on shares of Artivion from $47.00 to $53.00 and gave the stock a "market outperform" rating in a research report on Friday, November 7th. Canaccord Genuity Group decreased their price target on shares of Artivion from $51.00 to $48.00 and set a "buy" rating for the company in a research note on Friday, February 13th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $58.00 price objective on shares of Artivion in a research note on Monday, February 2nd. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $48.97.

Read Our Latest Stock Analysis on Artivion

Artivion News Summary

Here are the key news stories impacting Artivion this week:

Positive Sentiment: Company beat recent quarterly estimates — revenue grew ~19% year‑over‑year and EPS topped consensus in the Feb. 12 report, supporting the bullish case for revenue momentum and margin recovery. Earnings & Company Page
Positive Sentiment: Short interest fell materially in February (down ~15.4% month‑over‑month to ~1.39M shares, ~3.2% of float), lowering near‑term downside pressure from short covering and making upward moves easier to sustain. Short Interest/Insider Page
Positive Sentiment: Large institutional moves show conviction: several funds (Summit Partners, Invesco, Goldman, Two Sigma) increased or initiated sizeable positions in recent quarters, suggesting longer‑term buy interest from professional investors. Institutional Holdings
Neutral Sentiment: Analyst coverage is mixed but skewed positive: consensus is a “Moderate Buy” with a ~$49 average target, though several shops have trimmed price targets or moved to hold — signaling diverging views on near‑term upside. Analyst Notes
Negative Sentiment: Substantial insider selling across senior management over Feb. 23–24 (CEO James P. Mackin sold multiple blocks totaling tens of thousands of shares, plus sales by the EVP, SVPs and CAO). While filings indicate open‑market sales (liquidity/rebalancing), the size and breadth of the dispositions can create short‑term selling pressure and investor unease. SEC filings: CEO Form 4 and related officer filings. CEO Form 4 EVP Form 4

Institutional Trading of Artivion

A number of hedge funds have recently bought and sold shares of AORT. Invesco Ltd. increased its holdings in shares of Artivion by 211.9% in the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company's stock valued at $50,228,000 after acquiring an additional 748,119 shares during the period. XTX Topco Ltd purchased a new stake in shares of Artivion during the 4th quarter worth $746,000. Susquehanna Portfolio Strategies LLC boosted its position in Artivion by 21.5% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 40,542 shares of the company's stock valued at $1,849,000 after purchasing an additional 7,186 shares in the last quarter. Occudo Quantitative Strategies LP bought a new stake in Artivion during the fourth quarter valued at about $248,000. Finally, Millennium Management LLC grew its stake in Artivion by 1.0% in the fourth quarter. Millennium Management LLC now owns 91,816 shares of the company's stock valued at $4,188,000 after purchasing an additional 893 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company's stock.

About Artivion

(Get Free Report)

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.